PTX3 and graft versus host disease: Here, we have identified PTX3 as an easily measurable disease biomarker able to predict at onset of clinical symptoms, in a pediatric cohort of HSCT patients, the subsequent GvHD severity as well as the likelihood of refractoriness to standard therapy.